Product imageResearch use only

CAT. NO. DC33635Featured

DODAP

Research highlights

Three-component lipid coreHyaluronan-coated siRNA deliveryGL261-Luc in vitro RNAiCore N/P 4

Pack size & price

USD

Total$100

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

DODAP, also known as 1,2-Dioleoyl-3-dimethylammonium-propane, is a cationic lipid. It has been used as a component in liposomes that can be used to encapsulate siRNA, immunostimulatory oligodeoxynucleotides, antisense oligonucleotides, or chemotherapeutic agents for in vitro and in vivo delivery.

CAS No.	127512-29-2
Chemical Name	DODAP
Synonyms	18:1 DAP; DODAP (18:1); 1,2-Dioleoyl-3-dimethylammonium-propane;
SMILES	CN(CC(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O)C
Formula	C41H77NO4
M.Wt	648.07
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Passos Gibson V, et al. Modulating the Nature of Ionizable Lipids and Number of Layers in Hyaluronan-Decorated Lipid Nanoparticles for In Vitro Delivery of RNAi. Pharmaceutics. 2024;16(4):563.

View original study figures ↓

Literature-reported formulation composition

Component	mol%	Role
DODAP	50	Ionizable lipid
Cholesterol	39	Sterol
DOPE	11	Helper phospholipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
DODAP	50.000	89.8192	58.2091
Cholesterol	39.000	70.0590	27.0883
DOPE	11.000	19.7602	14.7026

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratio4

Total lipid:cargo weight ratioNot reported; not inferred from N/P 4.

Buffer & pH10 mM sodium acetate, pH 4, for the core aqueous phase and added siRNA. Poly-L-arginine and hyaluronic acid stocks in MilliQ water.

CargosiLuc in the core and first layer; scrambled siRNA controls

Administration routeIn vitro cell transfection only; no animal administration in this study

Dose180 nM siRNA/well; 48 h readout

Animal modelGL261-Luc murine glioblastoma cell line; no animal experiment

Formulation processInitial core: rapid hand-pipetting ethanol injection, 0.22 micromol total lipid, aqueous:ethanol 3:1 v/v, 15 min then dilute to 300 microlitres. Layering: 14.1 microlitres core suspension + 10 microlitres siRNA (20 micromolar), then 1 microlitre poly-L-arginine (2 mg/mL), then 5 microlitres hyaluronic acid (5 mg/mL); 10 min at room temperature after each layer.

Literature-reported performance for the cited formulation

Literature-reportedThree-layer particle diameter174 ± 1 nmMean ± SD; DLS Z-averageMain Results 3.1; Fig.1

Literature-reportedThree-layer PDI0.18 ± 0.01Mean ± SD; DLSMain Results 3.1; Fig.1

Literature-reportedCore siRNA encapsulation86 ± 1%SYBR Gold; disrupted versus intact coresMain Results 3.1; Fig.1

Literature-reportedLayer-associated siRNA (indirect)86 ± 1%Indirect SYBR Gold accessibility estimate; not a direct recovery assayMain Results 3.1; Fig.1

Literature-reportedResidual luciferase activity49 ± 1% of untreated cellsThree-layer HA-LNP; siLuc 180 nM; GL261-Luc cells · 48 h · Untreated cells; scrambled-siRNA particle controlMain Results 3.1; Fig.1

Initial core versus three-layer HA-LNP

Measurement	Initial core	Three-layer HA-LNP
Diameter (nm)	148 ± 2	174 ± 1
PDI	0.20 ± 0.01	0.18 ± 0.01
RNA assay (%)	86 ± 1 (core EE)	86 ± 1 (layer RNA; indirect)

Results 3.1; Fig.1. Mean ± SD. Core EE and layer-associated RNA are different assays.

Additional reported findings

Coating composition is additional to the lipid core

The 50/39/11 mol% table covers lipid core components only. To obtain the measured three-layer particles, 10 microlitres of 20 micromolar siRNA, 1 microlitre of 2 mg/mL poly-L-arginine and 5 microlitres of 5 mg/mL hyaluronic acid were added sequentially to 14.1 microlitres core suspension.

Ten minutes at room temperature after each layer · Methods 2.2

In vitro tolerability scope

No significant loss of cell viability was reported for the three-layer particles at 180 nM siRNA in the 48 h GL261-Luc assay. This is not systemic or long-term safety evidence.

WST-8 viability alongside luciferase assay · Methods 2.5; Results 3.1; Fig.1D

DODAP requires a different first-layer amount

Using 7 microlitres of 20 micromolar siRNA caused aggregation above 1 micrometre; increasing this to 10 microlitres enabled charge inversion and stable assembly. DODMA and MC3 used 7 microlitres.

14.1 microlitres core suspension; 10 mM acetate pH 4 · Discussion; Methods 2.2

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetPassos Gibson V, et al. Modulating the Nature of Ionizable Lipids and Number of Layers in Hyaluronan-Decorated Lipid Nanoparticles for In Vitro Delivery of RNAi. Pharmaceutics. 2024;16(4):563. DOI: 10.3390/pharmaceutics16040563
Only three-layer DODMA/DODAP evidence is presented. MC3-only SF188 and core-only efficacy results are excluded. N/P 4 is the initial core ratio.

Primary article and supplement

Published study figures

Original publication figures illustrating the cited formulation and biological results. Select an image to view it at full size.

Figure 3: DLinDMA (labelled DLin) is compared with KC2, MC3, DODMA and DODAP. Luciferase expression and cell viability are shown across mRNA doses; the particle-size and encapsulation measurements refer to the same study formulations. — Figure 3 — Cell expression, viability and LNP characteristics
DLinDMA (labelled DLin) is compared with KC2, MC3, DODMA and DODAP. Luciferase expression and cell viability are shown across mRNA doses; the particle-size and encapsulation measurements refer to the same study formulations. HEK293 cells; FLuc mRNA; N/P 4; 25–200 ng mRNA; 24-hour cell assessment; mean ± SD, n=3.
Carrasco et al. (2021), Communications Biology, Figure 3. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.

Figure 4: DLinDMA (DLin), MC3, DODMA and DODAP are individually labelled alongside KC2. The relative performance changes between intramuscular and intravenous administration; results should be read within the route and time point shown. — Figure 4 — Route-dependent reporter expression in mice
DLinDMA (DLin), MC3, DODMA and DODAP are individually labelled alongside KC2. The relative performance changes between intramuscular and intravenous administration; results should be read within the route and time point shown. 5 µg FLuc mRNA per mouse; N/P 4; IM or IV; measurements at 4 and 24 hours.
Carrasco et al. (2021), Communications Biology, Figure 4. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.

Figure 1B-D: Original panels compare DODMA-, MC3- and DODAP-based hyaluronan-decorated LNPs. Zeta potential, encapsulation-assay fluorescence and luciferase silencing are shown with their original controls. — Figure 1B-D — Original panels compare DODMA-, MC3- and DODAP-based hyaluronan-decorated LNPs
Original panels compare DODMA-, MC3- and DODAP-based hyaluronan-decorated LNPs. Zeta potential, encapsulation-assay fluorescence and luciferase silencing are shown with their original controls. GL261-Luc cells; 180 nM siRNA; 48 h. Bars show luciferase activity and connected points show viability, normalized to untreated cells.
Passos Gibson V et al. (2024). Layered LNP properties and cell silencing. Original article / figure · CC BY 4.0. Panels B-D cropped from the publisher PDF, page 5; panel A omitted. Original axes, labels, controls and statistics retained.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Lipid-core weights only (50/39/11 mol%). RNA, poly-L-arginine and hyaluronic acid are additional; coated-particle results cannot be assumed for the core alone. N/P 4 applies only before layering.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	15.4304 mL	3.0861 mL	1.5430 mL
25 mg	38.5761 mL	7.7152 mL	3.8576 mL
50 mg	77.1522 mL	15.4304 mL	7.7152 mL
100 mg	154.3043 mL	30.8609 mL	15.4304 mL
250 mg	385.7608 mL	77.1522 mL	38.5761 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

DODAP

Pack size & price

Description & Application

Recommended Products

DLin-MC3-DMA

DLin-KC2-DMA

DODMA

DMHAPC-Chol

503O13

L319

ATX-126(ATX-0126, lipid 10p)

Acuitas A9

C12-200

Arcturus lipid 2(ATX-0114)